Skip to main content

More men 'have oral cancer virus'

Oral human papillomavirus (HPV) infection is more common among men than women, leading to an increased risk for men of head and neck cancers, a US study suggests.
The Journal of the American Medical Association (JAMA) study assessed around 5,500 people aged 14 to 69.
Around 10% of men had oral HPV, compared with 3.6% of women.
HPV causes the majority of cervical cancers, as well as genital and anal - and head and neck cancers.
Smoking and drinking are significant known risk factors for head and neck cancers. But oral HPV infection increases cancer risk by around 50%, according to the research team from Ohio State University Comprehensive Cancer Center.
They say the incidence of head and neck cancers has significantly increased over the last three decades, and HPV has been directly implicated as an underlying cause.
The researchers used data from a cross-sectional study as part of the 2009-10 National Health and Nutrition Examination Survey.
They all provided a skin cell samples for testing from their mouths, and were interviewed about their lifestyles and sexual history.
Overall prevalence of oral HPV infection was 7%.
Prevalence of HPV increased with lifetime or recent number of partners for any kind of sex, vaginal sex, or oral sex.
Writing in JAMA, the team led by Dr Maura Gillison, said their findings should influence research into the existing HPV vaccines and how effective they could be in preventing oral cancers.
"Vaccine efficacy against oral HPV infection is unknown, and therefore vaccination cannot currently be recommended for the primary prevention of oropharyngeal cancer.
"Given an analysis of US cancer registry data recently projected that the number of HPV-positive oropharyngeal cancers diagnosed each year will surpass that of invasive cervical cancers by the year 2020, perhaps such vaccine trials are warranted."
Jessica Harris, health information manager at Cancer Research UK, said: "As we learn how common HPV infections in the mouth are, and how they are passed on, we can understand more about who is most at risk and how people can reduce the risk of HPV-related cancers.
"Although there isn't yet any evidence to show whether HPV vaccination is effective at preventing oral HPV infections, results like these are vital to help inform prevention programmes in the future."

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more